恒瑞医药(600276.SH)：注射用瑞康曲妥珠单抗药品上市许可申请获受理并纳入优先审评程序

Core Viewpoint - The company, Hengrui Medicine, has received acceptance for its drug application for injection of Rukang Qutuzumab, which is now included in the priority review process by the National Medical Products Administration [1] Group 1: Drug Approval - The company's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the acceptance notice for the drug listing application [1] - The injection of Rukang Qutuzumab is expected to be approved for market launch in China by May 2025 [1] - The drug is indicated for adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received at least one systemic therapy [1]